Back to results
US 2001/0056070 A1Published application
Method of administration of paclitaxel-plasma protein formulation
AssigneeTeva Pharmaceutical Industries Ltd.
InventorMoshe Flashner-Barak
Life of this patent
Estimating the term…
Abstract
The present invention provides for a method for treating human or animal patients with paclitaxel formulation, the method comprising an intratumoral dose of a paclitaxel formulation and an intravenous dose of paclitaxel. The intravenous dose occurs about 1 to about 7 days after the intratumoral dose. The paclitaxel formulation may typically be either a paclitaxel/HSA formulation or paclitaxel/γ-globulin formulation.
Claims19
A method of administering paclitaxel to a patient having a tumor, the method comprising;
- introducing an intratumoral dose of a paclitaxel formulation;
- and, subsequently providing an initial intravenous infusion of paclitaxel about 24 hours to about 7 days after the intratumoral dose.
Dependencies are inferred from the claim text.